Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...

Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), a $2 billion market cap biopharmaceutical company whose stock has surged 190% over the past year, recently sold 2,568 shares of the company's ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Canaccord raised the firm’s price target on Travere Therapeutics (TVTX) to $45 from $22 and keeps a Buy rating on the shares. The firm noted ...

State of Alaska Department of Revenue raised its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.0% during the 4th quarter, according to its most recent Form 13F filing ...

Travere Therapeutics aims to seek traditional approval based on data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI, with submission expected by the end of the first quarter of 2025. The ...